Quantum BioPharma Shareholders Approve Corporate Direction at Annual Meeting
Quantum BioPharma Ltd. secured full shareholder support for its strategic direction during its annual general meeting, highlighting investor confidence in the company's neurodegenerative and metabolic disorder treatments.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced the results of its annual general and special meeting of shareholders held September 26, 2025, in Toronto. The meeting demonstrated strong shareholder participation, with holders representing 12 Class A multiple voting shares and 1,769,228 Class B subordinate voting shares present in person or by proxy. This accounted for 100% of Class A votes and 46.352% of Class B votes, indicating substantial investor engagement with the company's strategic direction.
The significance of this shareholder meeting extends beyond routine corporate governance. Quantum BioPharma's focus on developing treatments for challenging neurodegenerative and metabolic disorders, along with alcohol misuse disorders, represents a critical area of unmet medical need. The company's research and development efforts through its wholly owned subsidiary, Lucid Psycheceuticals Inc., center on Lucid-MS, a patented new chemical entity that has shown promise in preclinical models for preventing and reversing myelin degradation—the underlying mechanism of multiple sclerosis.
Shareholder approval at this meeting provides crucial validation for Quantum BioPharma's business strategy, which includes maintaining its 20.11% ownership stake in Unbuzzd Wellness Inc. as of March 31, 2025. The company's agreement with Unbuzzd Wellness includes royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. This revenue stream supports the company's pharmaceutical research while Quantum BioPharma retains full rights to develop similar products for pharmaceutical and medical applications.
The company's diversified approach through FSD Strategic Investments Inc., its wholly owned subsidiary managing loans secured by residential or commercial property, provides additional financial stability. Investors seeking comprehensive information about Quantum BioPharma's developments can access detailed updates through the company's newsroom at https://ibn.fm/QNTM. The shareholder meeting outcomes signal continued investor confidence in Quantum BioPharma's ability to advance its pipeline of innovative biotech solutions for complex medical conditions.